Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer
2014 · European Journal of Cancer · 65 citations
https://doi.org/10.1016/j.ejca.2014.11.015